It is concluded that biomarker-driven precision diagnosis in axSpA requires continued biomarker discovery alongside the construction of shared infrastructure—multi-modal datasets, standardized pipelines, and prospective validation cohorts—to integrate existing and emerging biomarkers into clinically deployable tools.
Abstract
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints and spine, with an estimated global prevalence of 0.3–1.5%. Despite advances in classification criteria and imaging techniques, diagnostic delay remains a persistent clinical challenge, with patients waiting a median of 2–6 years from symptom onset to confirmed diagnosis. Biomarkers—broadly categorized into clinical, molecular, and imaging modalities—offer the potential to shorten this diagnostic gap by providing objective, quantifiable, and earlier indicators of disease. This narrative review maps the current landscape of biomarkers for the diagnosis of axSpA across all three modalities, with particular attention to how machine learning and multi-omics integration are reshaping the diagnostic paradigm. We examine established clinical markers (HLA-B27, inflammatory back pain criteria, C-reactive protein), survey the molecular biomarker literature spanning genomics, proteomics, metabolomics, and liquid biopsy, and trace the imaging trajectory from conventional radiography and MRI through to radiomics and deep learning models that now approach the performance of expert radiologists. We further explore multimodal fusion—the integration of clinical, molecular, and imaging biomarkers into unified diagnostic models—and identify barriers to clinical translation: the lack of prospective external validation, inconsistent standardization, and unresolved questions about algorithmic fairness across diverse populations. We conclude that biomarker-driven precision diagnosis in axSpA requires continued biomarker discovery alongside the construction of shared infrastructure—multi-modal datasets, standardized pipelines, and prospective validation cohorts—to integrate existing and emerging biomarkers into clinically deployable tools.
Axial spondyloarthritis (axSpA) assessment on MRI is complicated by interpretation difficulty and by clinical variables that may be incomplete at the time of imaging. We aimed to develop an image-only deep learning framework to approximate the clinical assessment of axSpA from sacroiliac joint (SIJ) MRI, integratin...
Yunseong Kim, Seulkee Lee, Seonyoung Kang et al.· Frontiers in Immunology· 0 citations
Adult spondylodiscitis is an infection of the intervertebral disc and adjacent vertebral bodies that may progress to paravertebral extension, epidural involvement, spinal instability, sepsis, and neurological compromise. Because clinical symptoms and laboratory markers are often nonspecific, imaging is central to diagn...
A. Al-ibraheem, E. Estrada-Lobato, S. Ruzzeh et al.· Seminars in nuclear medicine· 0 citations
This narrative review provides an updated overview of the pivotal role of imaging-detected tenosynovitis in the diagnosis and management of rheumatoid arthritis (RA). Tenosynovitis emerges as one of the earliest pathological events in inflammatory arthritis, and its histopathological features are indistinguishable fr...
N. P. B. de Andrade, R. M. da Silva Chakr, C. Brenol· Advances in Rheumatology· 0 citations
ABSTRACT Introduction Despite advances in understanding nociplastic pain and central sensitization, fibromyalgia remains a challenging clinical diagnosis due to the absence of specific biomarkers, extensive symptom overlap with other conditions, and persistent misconceptions about its pathophysiology. Areas covered Thi...
V. Segura-Jiménez· Expert Review of Neurotherap...· 0 citations
Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset, slowly progressive muscular dystrophy characterized by dysphagia, eyelid ptosis, and proximal limb weakness. Clinical trial readiness in OPMD requires development of sensitive indicators of disease progression and potential response to therapies in de...
I. Smith, Matthew Triolo, Karim Karimi et al.· Orphanet Journal of Rare Dis...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.